查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1362911

感染疾病物市場規模、佔有率和趨勢分析報告：按類型/藥物類別、給藥途徑、配銷通路管道、地區和細分市場預測，2023-2030年

Anti-infective Agents Market Size, Share & Trends Analysis Report By Type/Drug Class (Antivirals, Antifungals), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

感染疾病物市場成長及趨勢：

Grand View Research, Inc.最新報告顯示，預計到2030年，全球感染疾病物市場規模將達到1506億美元，2023年至2030年年複合成長率為1.2%。

HIV、H1N1 和伊波拉病毒等感染疾病的日益流行反映了近幾十年來社區行為模式的重大變化。社會變遷以及醫療保健專業人員和患者意識的提高正在推動成長。

世界衛生組織 (WHO) 和疾病管制與預防中心 (CDC) 等組織正在積極努力提高公眾對感染疾病致命影響和早期治療重要性的認知。 CDC 正在與國家衛生署(NHM) 合作，在巴西、中國、奈及利亞和印度等開發中國家宣感測染疾病的治療。

然而，研發線產品的商業化，例如效力和功效增強的新療法的推出，以及2018年用於治療社區獲得性細菌性肺炎（CABP）的omadacycline的商業化，預計將推動該領域的成長感染疾病物市場。

感染疾病物市場報告亮點

  • 由於愛滋病毒藥物 vicriviroc 等新型強效抗病毒藥物價格高昂，預計抗病毒藥物將成為最大的細分市場，到 2022 年，市場佔有率將達到 53.2%。
  • 抗生素領域預計在預測期內複合年複合成長率最快，達到 4.2%。抗生素已商業化，增加了處方數量並增加了可用性，預計這將進一步推動該領域。
  • 用於治療和預防嚴重和危及生命的感染疾病的組合藥物的開發預計將加速感染疾病物的使用。例如，2012年，吉利德科學公司推出了包含四種藥物（考比司他、艾替拉韋、恩曲他濱和富馬酸替諾福韋二吡呋酯）的綜合治療方法，用於治療未接受過逆轉錄病毒治療的愛滋病患者。我們也發布了一款新產品。
  • 由於新產品的開發和強大的產品平臺的存在，口服給藥途徑預計將在 2022 年成為最大的細分市場。
  • 醫院藥局以 2022 年收益佔有率最高的 28.8% 佔據市場主導地位，預計電子商務將成為預測期內成長最快的領域。
  • 2022年，北美地區在全球產業中佔據主導地位，佔最大佔有率，佔總收益的37.0%。感染疾病（包括兒童和成人的醫院感染）的高盛行率以及由此導致的抗生素過度使用和非處方箋抗感染藥物的獲取增加是主要促進因素。
  • 由於對新藥的大量未滿足的需求、快速發展的醫療基礎設施以及醫療保健專業人員和患者的意識不斷提高，亞太地區是成長最快的地區之一。
  • 有效的疾病管理需要多種長期策略，包括新產品開發、併購、共同開發和業務擴張。例如，2015年，ReViral從Wellcome Trust獲得2,100萬美元資金用於開發RV521。

目錄

第1章 調查方法與範圍

第2章 執行摘要

第3章 感染疾病市場變數、趨勢、範圍

  • 市場體系預測
    • 母市場預測
    • 相關/附隨市場預測
  • 普及和成長預測圖
  • 市場動態
    • 市場促進因素分析
    • 市場抑制因素分析
  • 感染疾病物市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章 感染疾病：種類/藥物類別的估計與趨勢分析

  • 感染疾病物市場：重點
  • 感染疾病物市場：2022年和2030年趨勢和市場佔有率分析
  • 抗菌劑
    • 2018-2030年抗菌劑市場預估及預測
    • 2018年至2030年抗菌劑類市場估計與預測
  • 抗病毒藥物
    • 2018年至2030年抗病毒藥物市場估計與預測
  • 抗真菌藥物
    • 2018年至2030年抗真菌藥物市場估計與預測
    • 2018年至2030年抗真菌藥物類市場估計與預測

第5章 感染疾病市場：給藥途徑預估及趨勢分析

  • 感染疾病物市場：重點
  • 感染疾病物市場：2022年和2030年趨勢和市場佔有率分析
  • 局部的
  • 口服
  • Ⅳ
  • 其他

第6章 感染疾病市場：配銷通路估算及趨勢分析

  • 感染疾病物市場：重點
  • 感染疾病物市場：2022年和2030年趨勢和市場佔有率分析
  • 醫院藥房
  • 零售藥房
  • 專業藥房
  • 電子商務
  • 其他

第7章 感染疾病市場：區域估算及趨勢分析

  • 區域預測
  • 感染疾病物市場（按區域）：重點
  • 北美洲
    • 2018-2030 年市場估計與預測
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 瑞典
    • 挪威
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 泰國
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭形勢

  • 主要市場參與企業的最新趨勢和影響分析
  • 市場參與企業分類
    • Pfizer Inc.
    • Abbott.
    • Gilead Sciences, Inc.
    • Bristol-Myers Squibb Company
    • Merck & Co., Inc.
    • Sandoz International GmbH
    • B. Braun SE
    • Xellia Pharmaceuticals
    • Mankind Pharma
    • Bayer AG
    • AstraZeneca
    • Boehringer Ingelheim International GmbH.
Product Code: 978-1-68038-973-9

Anti-infective Agents Market Growth & Trends:

The global anti-infective agents market size is expected to reach USD 150.6 billion by 2030, registering a CAGR of 1.2% from 2023 to 2030, according to a new report by Grand View Research, Inc.. Rising prevalence of infectious diseases such as HIV, H1N1, and Ebola virus reflect the profound changes in behavioral patterns of communities over the recent decades. The societal changes and increasing awareness among healthcare professionals and patients are driving the growth.

Organizations, such as the World Health Organization (WHO) and Centers for Disease control and Prevention (CDC) are actively involved in spreading awareness amongstpeople regarding the fatal implications of infectious diseases and the importance of early treatment. The CDC has collaborated with the National Health Ministry (NHM) in an attempt to spread awareness and to enhance the treatment of communicable diseases in developing countries such as Brazil, China, Nigeria, and India.

However, introduction of novel therapeutics with increased potency and efficacy and the commercialization of pipeline products, such as commercialization of Omadacycline in 2018 for the treatment of Community Acquired Bacterial Pneumonia (CABP), are expected to propel the growth of the anti-infective agents market.

Anti-infective Agents Market Report Highlights:

  • Antiviral was estimated to be the largest segment with a market share of 53.2% in 2022 owing to the high price associated with the new potent anti-viral drugs, such as Vicriviroc for the treatment of HIV
  • Antibacterial segment is anticipated to register the fastest CAGR of 4.2% during the forecast period, as antibacterial is the first line of treatment for a large range of infections. Increased prescription and accessibility of antibacterial due to their over-the-counter status is anticipated to further drive the segment
  • Development of combination drugs to treat and prevent serious and life-threatening infections is expected to propel the usage of anti-infective drugs. For instance, in 2012, Gilead Sciences, Inc. launched Stribild, a comprehensive treatment regimen inclusive of four drugs (cobicistat, elvitegravir, emtricitabine, and tenofovir disoproxil fumarate) used for the treatment of HIV patients without prior retroviral treatment record
  • Oral route of administration was estimated to be the held largest segment in 2022 owing to new product development and presence of strong product pipeline
  • Hospital pharmacy dominated the market with the highest revenue share of 28.8% in 2022 while e-commerce is expected to be the fastest-growing segment during the forecast period
  • North America dominated the global industry in 2022 and accounted for the largest share of 37.0% of the overall revenue. High prevalence of infectious diseases including hospital-acquired infections in both, children and adults, and the resultant overuse of antibiotics coupled with increased accessibility of non-prescription anti-infectives are the major drivers
  • Asia Pacific is one of the fastest growing regional segments owing to the presence of high, unmet demand for novel drugs, rapid improvements in healthcare infrastructure coupled with rising awareness among healthcare professionals and patients
  • Effective disease management involves a range of long-term strategies such as new product development, mergers and acquisitions, co-development, and business expansions. For instance, in 2015, ReViral received funding of USD 21 million for the development of its RV521 drug by the Wellcome Trust.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Type
    • 1.1.2. Route of Administration
    • 1.1.3. Distribution Channel
    • 1.1.4. Regional scope
    • 1.1.5. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary route of administrations
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type outlook
    • 2.2.2. Route of administration outlook
    • 2.2.3. Distribution channel outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Anti-Infective Agents Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market Driver Analysis
    • 3.3.2. Market Restraint Analysis
  • 3.4. Anti-Infective Agents Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic Landscape

Chapter 4. Anti-Infective Agents: Type/Drug Class Estimates & Trend Analysis

  • 4.1. Anti-Infective Agents Market: Key Takeaways
  • 4.2. Anti-Infective Agents Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Antibacterials
    • 4.3.1. Antibacterials market estimates and forecasts, 2018 to 2030 (USD Billion)
    • 4.3.2. Antibacterials drug class market estimates and forecasts, 2018 to 2030 (USD Billion)
      • 4.3.2.1. Cephalosporins
      • 4.3.2.1.1 Cephalosporins market estimates and forecasts, 2018 to 2030 (USD Billion)
      • 4.3.2.2. Penicillin
      • 4.3.2.2.1 Penicillin market estimates and forecasts, 2018 to 2030 (USD Billion)
      • 4.3.2.3. Fluoroquinolones
      • 4.3.2.2.2 Fluoroquinolones market estimates and forecasts, 2018 to 2030 (USD Billion)
      • 4.3.2.3 Macrolides
      • 4.3.2.3.1 Macrolides market estimates and forecasts, 2018 to 2030 (USD Billion)
      • 4.3.2.4 Carbapenem
      • 4.3.2.4.1 Carbapenem market estimates and forecasts, 2018 to 2030 (USD Billion)
      • 4.3.2.5 Others
      • 4.3.2.5.1 Others market estimates and forecasts, 2018 to 2030 (USD Billion)
  • 4.4. Antivirals
    • 4.4.1. Antivirals market estimates and forecasts, 2018 to 2030 (USD Billion)
  • 4.5. Antifungals
    • 4.5.1. Antifungals market estimates and forecasts, 2018 to 2030 (USD Billion)
    • 4.5.2. Antifungals drug class market estimates and forecasts, 2018 to 2030 (USD Billion)
      • 4.5.2.1. Azoles
      • 4.5.2.1.2 Azoles market estimates and forecasts, 2018 to 2030 (USD Billion)
      • 4.5.2.2. Echinocandins
      • 4.5.2.2.3 Echinocandins market estimates and forecasts, 2018 to 2030 (USD Billion)
      • 4.5.2.3. Polyenes
      • 4.5.2.2.4 Polyenes market estimates and forecasts, 2018 to 2030 (USD Billion)
      • 4.5.2.3 Others
      • 4.5.2.3.1 Others market estimates and forecasts, 2018 to 2030 (USD Billion)

Chapter 5. Anti-Infective Agents Market: Route of Administration Estimates & Trend Analysis

  • 5.1. Anti-Infective Agents Market: Key Takeaways
  • 5.2. Anti-Infective Agents Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Topical
    • 5.3.1. Topical market estimates and forecasts, 2018 to 2030 (USD Billion)
  • 5.4. Oral
    • 5.4.1. Oral market estimates and forecasts, 2018 to 2030 (USD Billion)
  • 5.5. IV
    • 5.5.1. IV market estimates and forecasts, 2018 to 2030 (USD Billion)
  • 5.6. Others
    • 5.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Billion)

Chapter 6. Anti-Infective Agents Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Anti-Infective Agents Market: Key Takeaways
  • 6.2. Anti-Infective Agents Market: Movement & Market Share Analysis, 2022 & 2030
  • 6.3. Hospital Pharmacies
    • 6.3.1. Hospital pharmacies market estimates and forecasts, 2018 to 2030 (USD Billion)
  • 6.4. Retail Pharmacies
    • 6.4.1. Retail pharmacies market estimates and forecasts, 2018 to 2030 (USD Billion)
  • 6.5. Specialty Pharmacies
    • 6.5.1. Specialty pharmacies market estimates and forecasts, 2018 to 2030 (USD Billion)
  • 6.6. E-Commerce
    • 6.6.1. Specialty pharmacies market estimates and forecasts, 2018 to 2030 (USD Billion)
  • 6.7. Others
    • 6.7.1. Other market estimates and forecasts, 2018 to 2030 (USD Billion)

Chapter 7. Anti-Infective Agents Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Outlook
  • 7.2. Anti-Infective Agents Market by Region: Key Takeaways
  • 7.3. North America
    • 7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 7.3.2. U.S.
      • 7.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 7.3.3. Canada
      • 7.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 7.4.2. Germany
      • 7.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 7.4.3. France
      • 7.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 7.4.4. Italy
      • 7.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 7.4.5. Spain
      • 7.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 7.4.6. Sweden
      • 7.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 7.4.7. Norway
      • 7.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 7.4.8. Denmark
      • 7.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 7.5.2. China
      • 7.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 7.5.3. India
      • 7.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 7.5.4. Australia
      • 7.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 7.5.5. Thailand
      • 7.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 7.5.6. South Korea
      • 7.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 7.6.2. Mexico
      • 7.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 7.6.3. Argentina
      • 7.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 7.7.3. UAE
      • 7.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 7.7.4. Kuwait
      • 7.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Market Participant Categorization
    • 8.2.1. Pfizer Inc.
      • 8.2.1.1. Company overview
      • 8.2.1.2. Financial performance
      • 8.2.1.3. Product benchmarking
      • 8.2.1.4. Strategic initiatives
    • 8.2.2. Abbott.
      • 8.2.2.1. Company overview
      • 8.2.2.2. Financial performance
      • 8.2.2.3. Product benchmarking
      • 8.2.2.4. Strategic initiatives
    • 8.2.3. Gilead Sciences, Inc.
      • 8.2.3.1. Company overview
      • 8.2.3.2. Financial performance
      • 8.2.3.3. Product benchmarking
      • 8.2.3.4. Strategic initiatives
    • 8.2.4. Bristol-Myers Squibb Company
      • 8.2.4.1. Company overview
      • 8.2.4.2. Financial performance
      • 8.2.4.3. Product benchmarking
      • 8.2.4.4. Strategic initiatives
    • 8.2.5. Merck & Co., Inc.
      • 8.2.5.1. Company overview
      • 8.2.5.2. Financial performance
      • 8.2.5.3. Product benchmarking
      • 8.2.5.4. Strategic initiatives
    • 8.2.6. Sandoz International GmbH
      • 8.2.6.1. Company overview
      • 8.2.6.2. Financial performance
      • 8.2.6.3. Product benchmarking
      • 8.2.6.4. Strategic initiatives
    • 8.2.7. B. Braun SE
      • 8.2.7.1. Company overview
      • 8.2.7.2. Financial performance
      • 8.2.7.3. Product benchmarking
      • 8.2.7.4. Strategic initiatives
    • 8.2.8. Xellia Pharmaceuticals
      • 8.2.8.1. Company overview
      • 8.2.8.2. Financial performance
      • 8.2.8.3. Product benchmarking
      • 8.2.8.4. Strategic initiatives
    • 8.2.9. Mankind Pharma
      • 8.2.9.1. Company overview
      • 8.2.9.2. Financial performance
      • 8.2.9.3. Product benchmarking
      • 8.2.9.4. Strategic initiatives
    • 8.2.10. Bayer AG
      • 8.2.10.1. Company overview
      • 8.2.10.2. Financial performance
      • 8.2.10.3. Product benchmarking
      • 8.2.10.4. Strategic initiatives
    • 8.2.11. AstraZeneca
      • 8.2.11.1. Company overview
      • 8.2.11.2. Financial performance
      • 8.2.11.3. Product benchmarking
      • 8.2.11.4. Strategic initiatives
    • 8.2.12. Boehringer Ingelheim International GmbH.
      • 8.2.12.1. Company overview
      • 8.2.12.2. Financial performance
      • 8.2.12.3. Product benchmarking
      • 8.2.12.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 North America anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 3 North America anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 4 North America anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 5 North America anti-infective agents market, by region, 2018 - 2030 (USD Billion)
  • Table 6 U.S. anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 7 U.S. anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 8 U.S. anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 9 Canada anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 10 Canada anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 11 Canada anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 12 Europe anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 13 Europe anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 14 Europe anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 15 Europe anti-infective agents market, by region, 2018 - 2030 (USD Billion)
  • Table 16 Germany anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 17 Germany anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 18 Germany anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 19 UK anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 20 UK anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 21 UK anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 22 France anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 23 France anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 24 France anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 25 Italy anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 26 Italy anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 27 Italy anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 28 Spain anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 29 Spain anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 30 Spain anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 31 Sweden anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 32 Sweden anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 33 Sweden anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 34 Norway anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 35 Norway anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 36 Norway anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 37 Denmark anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 38 Denmark anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 39 Denmark anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 40 Asia Pacific anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 41 Asia Pacific anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 42 Asia Pacific anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 43 Asia Pacific anti-infective agents market, by region, 2018 - 2030 (USD Billion)
  • Table 44 Japan anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 45 Japan anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 46 Japan anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 47 China anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 48 China anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 49 China anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 50 India anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 51 India anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 52 India anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 53 Australia anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 54 Australia anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 55 Australia anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 56 Thailand anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 57 Thailand anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 58 Thailand anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 59 South Korea anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 60 South Korea anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 61 South Korea anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 62 Latin America anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 63 Latin America anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 64 Latin America anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 65 Latin America anti-infective agents market, by region, 2018 - 2030 (USD Billion)
  • Table 66 Brazil anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 67 Brazil anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 68 Brazil anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 69 Mexico anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 70 Mexico anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 71 Mexico anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 72 Argentina anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 73 Argentina anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 74 Argentina anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 75 Middle East and Africa anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 76 Middle East and Africa anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 77 Middle East and Africa anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 78 Middle East and Africa anti-infective agents market, by region, 2018 - 2030 (USD Billion)
  • Table 79 South Africa anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 80 South Africa anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 81 South Africa anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 82 Saudi Arabia anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 83 Saudi Arabia anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 84 Saudi Arabia anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 85 UAE anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 86 UAE anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 87 UAE anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 88 Kuwait anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 89 Kuwait anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 90 Kuwait anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Anti-infective agents: Market outlook
  • Fig. 9 Anti-infective agents: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Anti-infective agents market driver impact
  • Fig. 15 Anti-infective agents market restraint impact
  • Fig. 16 Anti-infective agents market strategic Initiatives analysis
  • Fig. 17 Anti-infective agents market: Type movement analysis
  • Fig. 18 Anti-infective agents market: Type outlook and key takeaways
  • Fig. 19 Antibacterials market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 20 Antibacterials drug class market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 21 Cephalosporins market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 22 Penicillin market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 23 Fluoroquinolones market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 24 Macrolides market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 25 Carbapenems market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 26 Others market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 27 Antivirals market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 28 Antifungals market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 29 Cephalosporins market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 30 Penicillin market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 31 Fluoroquinolones market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 32 Macrolides market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 33 Carbapenems market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 34 Others market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 35 Anti-infective agents market: Route of administration movement analysis
  • Fig. 36 Anti-infective agents market: Route of administration outlook and key takeaways
  • Fig. 37 Topical market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 38 Oral market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 39 IV market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 40 Others market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 41 Anti-infective agents market: Distribution channel movement analysis
  • Fig. 42 Anti-infective agents market: Distribution channel outlook and key takeaways
  • Fig. 43 Hospital pharmacies market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 44 Retail pharmacies market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 45 Specialty pharmacies market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 46 E-commerce market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 47 Others market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 48 Global anti-infective agents market: Regional movement analysis
  • Fig. 49 Global anti-infective agents market: Regional outlook and key takeaways
  • Fig. 50 North America market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 51 U.S. market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 52 Canada market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 53 Europe. market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 54 UK market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 55 Germany market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 56 France market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 57 Italy market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 58 Spain market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 59 Sweden market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 60 Norway market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 61 Denmark market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 62 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 63 Japan market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 64 China market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 65 India market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 66 Australia market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 67 Thailand market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 68 South Korea market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 69 Latin America market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 70 Brazil market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 71 Mexico market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 72 Argentina market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 73 Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 74 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 75 South Africa market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 76 UAE market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 77 Kuwait market estimates and forecasts, 2018 - 2030 (USD Billion)